SIMPLE Study: Impact of Saline Infusion on ME/CFS, POTS and Long COVID

Several trial treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) have utilized saline, with the placebo within those trials also being saline. Consequently, these placebos have shown high improvement levels, suggesting a significant placebo effect. Additionally, many patients, including those with ME/CFS, Long COVID, and Postural Orthostatic Tachycardia Syndrome (POTS), respond positively to saline infusion. Therefore, investigating the impact of saline on these conditions is valuable.

Saline’s rapid improvement in these patients allows for the observation of objective measures of improvement within a short timeframe. This study proposes to trial different saline formulations, including a placebo sham saline, saline alone, saline with dextrose, and Hartmann’s solution, in the same individuals. By comparing their effectiveness beyond placebo, we aim to understand which types of saline or treatments are most beneficial for individuals and why.

Detailing the impact of saline infusion can elucidate its efficacy, identify patient populations most likely to benefit, and characterize its effects for future trials involving saline. This study has the potential to inform clinical practice and improve treatment strategies for individuals with ME/CFS, Long COVID, and POTS.